PRSS3 promotes tumour growth and metastasis of human pancreatic cancer

Guozhong Jiang ¹, Fengyu Cao , Guoping Ren

⁰The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Gut +

|

October 16, 2010

View abstract on PubMed

Summary

Over-expression of PRSS3 promotes pancreatic cancer growth and metastasis by upregulating VEGF via the ERK pathway. Targeting this pathway offers a potential therapeutic strategy for pancreatic cancer treatment.

Area Of Science

Oncology
Molecular Biology
Cancer Research

Background

Metastasis significantly worsens patient outcomes in pancreatic cancer.
PRSS3 (Protease Serine 3) is identified as over-expressed in metastatic pancreatic cancer cells.

Purpose Of The Study

To investigate the role of PRSS3 in human pancreatic cancer growth and metastasis.
To elucidate the signaling pathway involved in PRSS3-mediated metastasis.

Main Methods

PRSS3 expression analyzed using qPCR, immunoblotting, and immunohistochemistry.
In vitro and in vivo models used to assess PRSS3's effect on proliferation, migration, invasion, tumor growth, and metastasis.
VEGF expression and the PAR1-ERK pathway investigated for PRSS3's mechanism of action.

Main Results

PRSS3 over-expression correlated with increased pancreatic cancer cell proliferation, invasion, tumor progression, and metastasis.
PRSS3 upregulates VEGF via the PAR1-ERK pathway.
ERK inhibition significantly reduced metastasis and prolonged survival in vivo.
PRSS3 expression was detected in 40.54% of human pancreatic cancer tissues and correlated significantly with metastasis and poorer survival.

Conclusions

PRSS3 is a key driver of pancreatic cancer progression, metastasis, and poor prognosis.
Targeting the PRSS3 signaling pathway presents a promising therapeutic avenue for pancreatic cancer.

Related Concept Videos